# Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

> **NCT06015750** · PHASE4 · WITHDRAWN · sponsor: **Alexion Pharmaceuticals, Inc.**

## Conditions studied

- Hypophosphatasia

## Interventions

- **DRUG:** methotrexate
- **DRUG:** rituximab
- **DRUG:** bortezomib
- **DRUG:** IVIg
- **DRUG:** Folic Acid

## Key facts

- **NCT ID:** NCT06015750
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-07-29
- **Primary completion:** 2030-03-13
- **Final completion:** 2030-03-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision following FDA release from the PMR.
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06015750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06015750, "Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06015750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*